ARCH Venture Partners
ARCH Venture Partners is an early-stage venture capital firm founded in 1986 that co-founds and invests in life sciences, biotechnology, AI, and deep-tech companies, providing multi-stage capital from seed to commercial stages across 230+ portfolio companies worldwide.
- Company typePrivate
- Founded1986
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ARCH Venture Partners does
ARCH Venture Partners is a privately held venture capital firm headquartered in Chicago, Illinois, with a second office in Mercer Island (Seattle), Washington. Founded in 1986 by Steven Lazarus at the University of Chicago and Argonne National Laboratory as the Argonne-Chicago (ARCH) Development Corporation to commercialize academic and national laboratory research, the firm was reorganized as a private partnership in 1992. ARCH specializes in the early-stage formation, funding, and development of disruptive life sciences and technology companies, co-founding businesses alongside leading scientists and entrepreneurs and providing multi-stage capital from as little as $50K at seed to hundreds of millions of dollars per company. The firm operates a series of venture capital funds — most recently ARCH Venture Fund XIII at more than $3 billion (September 2024), preceded by Fund XII ($2.975B, 2022), Fund XI ($1.85B+, 2021), and Funds X and X Overage ($1.46B combined, 2020) — and has built more than 230 portfolio companies across biotechnology, life sciences tools, AI-driven drug discovery, quantum computing, and physical AI.
ARCH generates revenue through management fees on committed fund capital and carried interest on successful portfolio exits, a standard venture capital economic model. Its capital is sourced from institutional limited partners including endowments, family offices, sovereign wealth funds, and other institutional investors via private placement. Beyond its funds, the firm operates ARCH Strategic Partnerships (ASP), an initiative providing consulting services to corporate industry leaders to foster relationships with early-stage scientific innovators and surface dealflow — a complementary revenue and partnership channel to the firm's core company-co-founding model. Go-to-market is relationship-driven: deal sourcing depends on ARCH's network of academic institutions (notably the University of Chicago and Argonne National Laboratory), national research laboratories, corporate research groups, and repeat entrepreneurs, with the firm typically leading or co-leading rounds and taking board seats. Notable portfolio companies include Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Vir Biotechnology, Karuna Therapeutics, Beam Therapeutics, Sana Biotechnology, Twist Bioscience, GRAIL, Xaira Therapeutics, Prometheus, and D-Wave (via Quantum Circuits), with co-founder Robert Nelsen having personally played a role in more than 150 company creations.
The firm is led by co-founders and Managing Directors Robert Nelsen, Keith Crandell, and Clinton Bybee (Emeritus), with additional Managing Directors Kristina Burow, Steve Gillis, Paul Berns, and Mark McDonnell (CFO and CAO), supported by a deep bench of Partners, Venture Partners, and Senior Advisors including John Maraganore (founding CEO of Alnylam) and Brian Cuneo (former Latham & Watkins Life Sciences chair). ARCH has expanded its geographic reach globally — with portfolio companies in the US, UK, China, Sweden, Singapore, and Switzerland — and has broadened its thematic scope from biotech into AI-driven drug discovery, quantum computing, and physical AI through flagship investments such as Xaira Therapeutics, Prometheus, and Quantum Circuits.
ARCH Venture Partners firmographics
Firmographics- Name
- ARCH Venture Partners
- Legal name
- ARCH Venture Partners
- Website
- http://www.archventure.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ARCH Venture Partners is an early-stage venture capital firm founded in 1986 that co-founds and invests in life sciences, biotechnology, AI, and deep-tech companies, providing multi-stage capital from seed to commercial stages across 230+ portfolio companies worldwide.
- Ownership category
- akta.pro rank
ARCH Venture Partners industry classification
Industry- Product category
- Venture Capital
- akta.pro primary industry
- Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)
- akta.pro secondary industry
- Venture Capital Fundraising Placement (FSAEALAC)
Keywords
Where ARCH Venture Partners is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Markets served
ARCH Venture Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Others
Revenue model
- Venture fund management and carried interest: ARCH Venture Partners generates revenue as a venture capital firm through management fees on committed fund capital and carried interest (equity participation) on successful exits from portfolio companies. The firm has raised multiple multi-billion-dollar funds (Fund VIII through Fund XIII) ranging from $560 million to $3 billion each, investing primarily in companies it co-founds with leading scientists and entrepreneurs.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ARCH Venture Partners product offering
Product offeringCore offering
ARCH Venture Partners is a venture capital firm that co-founds and invests in early-stage life sciences, physical sciences, and technology companies, deploying multi-stage capital ranging from $50,000 to hundreds of millions of dollars per company. The firm raises and manages a series of venture capital funds (Fund VIII through Fund XIII) from institutional limited partners and partners with leading scientists, entrepreneurs, academic institutions, and national laboratories to commercialize breakthrough research into viable companies. ARCH Strategic Partnerships (ASP) supplements the funds by providing consulting services to corporate industry leaders seeking collaboration with early-stage scientific innovators.
Product overview
ARCH Venture Partners is an early-stage technology venture firm that creates and invests in groundbreaking life science and technology companies. Its offerings center on a series of venture capital funds — most recently ARCH Venture Fund XIII ($3B+), preceded by Fund XII ($2.975B), Fund XI ($1.85B+), and Fund X and Fund X Overage (combined $1.46B) — that finance the founding and growth of disruptive early-stage biotechnology companies. Complementing the funds, ARCH Strategic Partnerships (ASP) is a consulting initiative that helps corporations collaborate with early-stage scientific innovators and bring discoveries to market. Together, the funds provide the capital foundation for ARCH's portfolio of more than 230 companies, while ASP extends the firm's expertise into corporate venture building.
Differentiator
Problem solved
Functional benefit
Brands
- ARCH Strategic Partnerships (ASP): An ARCH initiative that provides consulting services to corporations building innovation-driven technology commercialization and business development practices globally, fostering relationships between industry leaders and early-stage scientific innovators.
Products and services
- ARCH Venture Fund XIII A venture capital fund with more than $3 billion committed to support the founding and growth of early-stage biotechnology companies; to-date investments include ArsenalBio, Metsera, Mirador Therapeutics, and Xaira Therapeutics.
- ARCH Venture Fund XII A $2.975 billion venture capital fund to invest in the creation, development, and funding of early-stage biotechnology companies across infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, diagnostics, and therapies.
- ARCH Venture Fund XI A venture capital fund with over $1.85 billion committed to invest in the creation and funding of early-stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, diagnostics, and therapies.
- ARCH Venture Fund X and Fund X Overage Two paired venture capital funds with a combined $1.46 billion to invest in transformative, early-stage biotechnology companies; the Overage is deployed in fewer deals requiring larger investments.
- ARCH Strategic Partnerships (ASP) A consulting and corporate-relations initiative that helps corporations build innovation-driven technology commercialization and business development practices, providing access to ARCH's dealflow and early-stage scientific innovators for collaboration.
Quantifiable outcome
- More than 230 companies built since 1986
- +2 more outcomes
Companies that use ARCH Venture Partners
Customer profileSegments4 records
Ideal customer profiles4 records
ARCH Venture Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ARCH Venture Partners partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, core and minor.
- Project Prometheus (Bezos-backed physical AI)flagshipARCH participated in Prometheus's $12 billion Series B at a $41 billion valuation, alongside JPMorgan Chase, Goldman Sachs, BlackRock, DST Global, and Bezos. ARCH co-founder Robert Nelsen is co-founder of Project Prometheus and serves as a director. Prometheus is developing an "artificial general engineer" to automate design and manufacturing.
- Massachusetts General Hospital (MGH)coreMassachusetts General Hospital is the source institution for Altido Bio's CAR-T therapy for glioblastoma. ARCH led Altido Bio's $12.5 million seed round to advance an MGH-developed CAR-T therapy. ARCH maintains broader strategic ties to Mass General via Keith Crandell's role on the Mass General Brigham Innovation Fund Investment Advisory Board.
- ARCH Strategic Partnerships (ASP) corporate partnerscoreARCH Strategic Partnerships (ASP) is an ARCH initiative providing consulting services to corporate industry leaders and fostering relationships between them and early-stage scientific innovators. ASP corporate partners gain access to innovation, dealflow, industry experts, collaborations, and have started corporate venture capital teams. They strategically partner with innovative companies in the ARCH portfolio and beyond.
- Polsky Center for Entrepreneurship, Chicago Booth / University of Chicago Pritzker School of Molecular EngineeringcoreARCH co-founder Keith Crandell has served on the Entrepreneurship Advisory Board at the Polsky Center for Entrepreneurship at ChicagoBooth since 2005 and on the University of Chicago Pritzker School of Molecular Engineering Advisory Council since 2017. These partnerships support ARCH's pipeline of academic spinouts.
- D-Wave QuantumminorD-Wave Quantum acquired ARCH-backed Quantum Circuits to accelerate the development of quantum computers (announced January 7, 2026). Quantum Circuits was originally co-founded by ARCH, F-Prime, Sequoia Capital, and Hither Creek Ventures.
- University of Chicago / Argonne National LaboratorycoreFounding institutional partnership. ARCH was created in 1986 by Steven Lazarus at the University of Chicago with Walter Massey and the Trustees, originally as the Argonne-Chicago (ARCH) Development Corporation, to commercialize technologies developed at these institutions. Keith Crandell serves on the Polsky Center for Entrepreneurship Advisory Board and the University of Chicago Pritzker School of Molecular Engineering Advisory Council. The firm remains "a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories."
- Endpoints 11 (Dispatch Bio and Sironax) — 2025 winnersminorTwo ARCH-backed companies — Dispatch Bio and Sironax — named to the Endpoints 11 list of most exciting startups in 2025, validating ARCH's biotech portfolio.
- Irish government consortiumminorARCH established its European office in Dublin, Ireland in 2011 led by the late Managing Director Paul Thurk, working with an Irish government consortium to identify and build businesses from Ireland-based academic institutions. Resulted in co-founding of Carrick Therapeutics, Genomics Medicine Ireland, and Pretzel Therapeutics.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
ARCH Venture Partners competitors and assessment
Company assessmentDirect peers
- Flagship Pioneering: Flagship Pioneering is the closest direct peer — a private venture firm that creates and funds platform biotech companies (Moderna, Generate Biomedicines, Tessera Therapeutics) from proprietary science, raising large multi-billion-dollar funds. Both ARCH and Flagship operate a company-creation (rather than traditional financial-investor) model, co-found breakthrough life sciences ventures, and invest from inception through public stages.
- Third Rock Ventures: Third Rock Ventures is a direct peer — a biotech-focused venture firm that builds companies from scratch around breakthrough science, similar to ARCH's company-creation approach. Both firms co-found life sciences companies, take deep operational roles, and focus on platform technologies in therapeutics and diagnostics.
- Atlas Venture: Atlas Venture is a direct peer — an early-stage biotech venture firm that builds and funds breakthrough therapeutics companies from inception. Like ARCH, Atlas focuses on company creation, takes board seats, and concentrates on life sciences with concentrated portfolio construction around platform technologies.
- OrbiMed: OrbiMed is a direct peer — a healthcare-dedicated investment firm managing multi-billion-dollar funds across the life sciences continuum from venture to public equity. Like ARCH, OrbiMed invests across stages in biotech, medical devices, and diagnostics, and is a frequent co-investor in ARCH's portfolio companies.
- RA Capital Management: RA Capital is a direct peer — a healthcare-focused investment manager that combines venture capital with public equity and crossover investing. RA Capital is one of ARCH's most frequent co-investors (Parabilis, Ollin, nChroma), making the two firms directly comparable in stage, focus, and syndicate behavior.
- Versant Ventures: Versant Ventures is a direct peer — a healthcare-focused venture firm that builds biotech companies from inception with offices in North America and Europe. Like ARCH, Versant operates a company-creation model, often co-founds ventures around academic science, and deploys multi-hundred-million-dollar funds concentrated in therapeutics.
- Andreessen Horowitz (a16z Bio+Health): Andreessen Horowitz's Bio+Health fund is an emerging direct peer — a major generalist VC that has aggressively expanded into early-stage biotech and digital health with multi-billion-dollar dedicated funds. a16z Bio+Health participates in many of ARCH's later rounds (e.g., Ollin Biosciences, Xaira) and competes for the same early-stage company-creation deals.
- Foresite Capital: Foresite Capital is a direct peer — a healthcare and life sciences-focused investment firm that has built and backed multiple biotech platforms from early stage to IPO. Like ARCH, Foresite concentrates on breakthrough science with deep operating involvement, often co-founding companies around novel therapeutics.
- Deerfield Management: Deerfield Management is a direct peer — a healthcare-focused investment firm with multiple fund vehicles covering public and private biotech, medical devices, and healthcare services. Like ARCH, Deerfield invests across all stages of company development in life sciences and frequently co-invests in ARCH-led rounds.
Emerging players
- Lux Capital: Lux Capital is an emerging peer in life sciences venture — primarily a deep-tech investor that has built out a life sciences practice investing in biotech, neurotechnology, and healthcare AI. Lux is a frequent co-investor with ARCH (e.g., Paradigm Health), though it maintains a broader technology focus beyond biotech.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
ARCH Venture Partners social profiles
Digital presenceARCH Venture Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARCH Venture Partners leadership team
Management profileNumber of profiles
Profiles15 records
ARCH Venture Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
ARCH Venture Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARCH Venture Partners M&A and investment
M&A and investmentM&A
Investments564 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARCH Venture Partners
What does ARCH Venture Partners do?
ARCH Venture Partners is a venture capital firm that co-founds and invests in early-stage life sciences, physical sciences, and technology companies, deploying multi-stage capital ranging from $50,000 to hundreds of millions of dollars per company. The firm raises and manages a series of venture capital funds (Fund VIII through Fund XIII) from institutional limited partners and partners with leading scientists, entrepreneurs, academic institutions, and national laboratories to commercialize breakthrough research into viable companies. ARCH Strategic Partnerships (ASP) supplements the funds by providing consulting services to corporate industry leaders seeking collaboration with early-stage scientific innovators.
Is ARCH Venture Partners a public or private company?
ARCH Venture Partners is a private company. It is classified as management employee owned and is currently operating.
When was ARCH Venture Partners founded?
ARCH Venture Partners was founded in 1986. It employs 11 to 50 people.
Where is ARCH Venture Partners based?
ARCH Venture Partners is headquartered in Chicago, United States, in the North America region.
How does ARCH Venture Partners make money?
One revenue line is on record: venture fund management and carried interest.
Who are ARCH Venture Partners's main competitors?
Direct peers on record are Flagship Pioneering, Third Rock Ventures, Atlas Venture, OrbiMed, RA Capital Management, Versant Ventures, Andreessen Horowitz (a16z Bio+Health), Foresite Capital and Deerfield Management. Lux Capital is listed as an emerging player.
Does ARCH Venture Partners have an API?
No public API is recorded for ARCH Venture Partners.
What industry is ARCH Venture Partners in?
ARCH Venture Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms, with a secondary code of FSAEALAC, Venture Capital Fundraising Placement.